This brand name is authorized in Estonia, Ireland, Romania
The drug LERCARIL contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Enalapril
UNII 9O25354EPJ - ENALAPRIL MALEATE
|
|
Enalapril is hydrolysed via hepatic CES 1 to the active metabolite enalaprilat, which acts as an ACE inhibitor. ACE is a peptidyl dipeptidase which catalyses the conversion of angiotensin I to the vasoconstrictor substance angiotensin II and hence inhibition of ACE results in decreased plasma angiotensin II. This also leads to increased plasma renin activity and decreased aldosterone secretion. The mechanism of action of enalapril is therefore primarily via the suppression of the RAAS. However, ACE is identical to kininase II, and so enalapril may also exert its effects by blocking the degradation of bradykinin, a potent vasodepressor peptide. |
|
2
Lercanidipine
UNII OA8TFX68PE - LERCANIDIPINE HYDROCHLORIDE
|
|
Lercanidipine is a calcium antagonist of the dihydropyridine group and inhibits the transmembrane influx of calcium into cardiac and smooth muscle. The mechanism of its antihypertensive action is due to a direct relaxant effect on vascular smooth muscle thus lowering total peripheral resistance. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| LERCARIL 20 mg/10 mg Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| LERCARIL 10 mg/10 mg Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| LERCARIL 20 mg/20 mg Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C09BB02 | Enalapril and lercanidipine | C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09B ACE inhibitors, combinations → C09BB ACE inhibitors and calcium channel blockers |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EE | Ravimiamet | Identifier(s): 1312827, 1312838, 1312849, 1312850, 1312861, 1312872, 1312883, 1312894, 1312906, 1312917, 1312928, 1312939, 1312940, 1312951, 1312962, 1312973, 1312984, 1312995, 1313008, 1313019, 1313020, 1313031, 1599431, 1599442, 1599453, 1599464, 1599475, 1599486, 1599497, 1599509, 1599510, 1599521, 1599532 |
| Country: IE | Health Products Regulatory Authority | Identifier(s): 31470, 31482, 43781 |
| Country: RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | Identifier(s): W53228001, W53228002, W53228003, W53228004, W53228005, W53228006, W53228007, W53228008, W53228009, W53228010, W53228011, W53229001, W53229002, W53229003, W53229004, W53229005, W53229006, W53229007, W53229008, W53229009, W53229010, W53229011, W61013001, W61013002, W61013003, W61013004, W61013005, W61013006, W61013007, W61013008, W61013009, W61013010, W61013011 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
